Table 1.
Baseline characteristics and medical history (safety population, N = 87)
| Safety population (N = 87) | |
|---|---|
| Age (years), mean (SD) | 60.2 (10.05) |
| Men, n (%) | 56 (64.4) |
| Time since AF diagnosis (months), mean (SD) | 48.9 (51.26) |
| CHA2DS2-VASc score, mean (SD) | 1.4 (1.23) |
| Left atrial diameter (mm), mean (SD) | 38.5 (5.32) |
| Left ventricle ejection fraction (%), mean (SD) | 61.1 (4.84) |
| Pharmacological cardioversion in the past 12 months, n (%) | 8 (9.2) |
| Direct current cardioversion in the past 12 months, n (%) | 4 (4.6) |
| Number of AADs failed, mean (SD) | 1.3 (0.55) |
| Class I/III AADs, n (%) | 50 (57.5) |
| Comorbidities, n (%) | |
| Coronary artery disease | 3 (3.4) |
| Congestive heart failure, NYHA Class I | 1 (1.1) |
| Hypertension | 42 (48.3) |
| Type II diabetes mellitus | 8 (9.2) |
| Thromboembolic events | 4 (4.6) |
| Atrial flutter | 7 (8.0) |
| Obstructive sleep apnoea | 1 (1.1) |
AAD, antiarrhythmic drug; AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischaemic attack/thromboembolism, vascular disease, age 65–74 years, sex category; NYHA, New York Heart Association; SD, standard deviation.